GT Biopharma Inc (GTBP)

Over the past six months, GT Biopharma's stock price has significantly declined. The stock's 52-week range has been between $0.40 and $3.85, and as of February 6, 2026, the share price was $0.53. The FDA clearance of an IND application for GTB-5550 TriKE® was a notable event. The stock has shown negative signals from Moving Averages and made new lows multiple times.

Information regarding demand seasonality for GT Biopharma, Inc.'s products and services was not available. Demand is typically driven by clinical trial progress, regulatory approvals, and disease prevalence rather than seasonal factors.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology products, operating within the Health Technology sector. Its therapeutic products utilize TriKE® and Dual Targeting TriKE platforms to enhance the cancer-killing abilities of NK cells. The company's pipeline includes GTB-3650 targeting CD33, GTB-5550 targeting B7-H3, GTB-7550 for lupus and autoimmune disorders, and GTB-3550 for AML, MDS, and other CD33+ hematologic cancers.

GT Biopharma, Inc. is based in San Francisco, California, and focuses on developing and commercializing immuno-oncology products in the United States. It holds an exclusive worldwide license agreement with the University of Minnesota for its TriKE® technology.

GT Biopharma's brand reputation has faced challenges, reflected by analyst sentiment and stock performance. The company has an average brokerage recommendation of 2.00, with a consensus "Sell" rating among analysts. Another source indicates a "Very Bullish" average rating from one analyst, suggesting a "buy" consensus. Zacks Investment Research rates GT Biopharma as a Zacks Rank 3 ("Hold") and suggests it may be overvalued. The company has underperformed both the US Biotechs industry and the broader US Market over the past year.

GT Biopharma, Inc. has 32 institutional owners and shareholders holding a total of 477,712 shares. Institutional investors own approximately 0.86% to 0.93% of the company's stock, insiders own 8.05%, and public companies and individual investors own 0.07% to 91.02%. Major institutional shareholders include DRW Securities, LLC, Bank Of Montreal, Seacrest Wealth Management, Llc, Citadel Advisors Llc, Geode Capital Management, Llc, Two Sigma Securities, Llc, Morgan Stanley, Parsons Capital Management Inc/ri, Vanguard Group Inc, Coston, McIsaac & Partners, Am Investment Strategies Llc, and Verdence Capital Advisors LLC. Michael Martin Breen, the CEO, owns the most shares among individuals.